Arcutis Biotherapeutics, Inc. (ARQT) — 8-K Filings

8-K Filings (10)

• Arcutis Biotherapeutics Reports Director Departure and New Election — Dec 8, 2025 Risk: low
  Arcutis Biotherapeutics, Inc. filed an 8-K on December 8, 2025, reporting on the departure of Director Michael J. Smith and the election of new director, Dr. Da
• Arcutis Biotherapeutics Files 8-K — Jun 17, 2025 Risk: low
  Arcutis Biotherapeutics, Inc. filed an 8-K on June 17, 2025, reporting on events that occurred on June 12, 2025. The filing indicates that the company submitted
• Arcutis Biotherapeutics Announces Director Changes — Apr 10, 2025 Risk: low
  Arcutis Biotherapeutics, Inc. announced on April 10, 2025, the departure of Director David M. M. Clapper and the election of new Director Michael J. Miller. The
• Arcutis Biotherapeutics Files 8-K on Financials — Jan 13, 2025 Risk: low
  Arcutis Biotherapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition as of January 12, 2025. The filin
• Arcutis Biotherapeutics Files 8-K on Shareholder Matters — Jun 18, 2024 Risk: low
  Arcutis Biotherapeutics, Inc. filed an 8-K on June 18, 2024, reporting on matters submitted to a vote of security holders as of June 14, 2024. The filing detail
• Arcutis Biotherapeutics Appoints New CMO, Reports Officer Changes — Apr 10, 2024 Risk: medium
  Arcutis Biotherapeutics, Inc. announced on April 10, 2024, the appointment of Scott B. Stein as Chief Medical Officer and the departure of Dr. Patrick Mooney fr
• Arcutis Biotherapeutics Files 8-K — Mar 4, 2024 Risk: low
  Arcutis Biotherapeutics, Inc. filed an 8-K on February 28, 2024, reporting other events and financial statements. The filing details the company's corporate str
• Arcutis Biotherapeutics Enters Material Definitive Agreement — Feb 28, 2024 Risk: medium
  Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) filed an 8-K on February 28, 2024, reporting an "Entry into a Material Definitive Agreement" on February 27, 2024.
• Arcutis Reports Officer/Director Changes & Compensation — Feb 15, 2024 Risk: medium
  Arcutis Biotherapeutics, Inc. filed an 8-K on February 15, 2024, reporting events from February 12, 2024, concerning the departure or election of directors or o
• Arcutis Signals Potential Tender Offer with 8-K Filing — Jan 11, 2024
  Arcutis Biotherapeutics, Inc. filed an 8-K on January 11, 2024, indicating it is engaging in "Pre-commencement communications pursuant to Rule 13e-4(c) under th

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX